CSXY 0002
Alternative Names: CSXY-0002Latest Information Update: 24 Feb 2023
At a glance
- Originator Chipscreen Biosciences
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Jan 2023 Preclinical trials in Cancer in China (Parenteral) (Chipscreen Biosciences Pipeline, January 2023)